Advanced Treatment Strategies for Asthma
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: 5 May 2025 | Viewed by 55
Special Issue Editor
Interests: asthma inhalation therapy; biological therapy; immunological mechanisms; inhalation instruction; inhalation guidance coordination system
Special Issue Information
Dear Colleagues,
Inhalation therapy is central to asthma treatment, as indicated by international guidelines such as the Global Initiative for Asthma (GINA). In recent years, triple-inhalation medications (ICS/LABA/LAMA) have become widely used in clinical practice, expected to achieve the treatment goal of clinical remission. Additionally, to achieve early-stage complete remission, the complete control of asthma-related inflammation is also required. Two main themes need to be addressed: (1) increasing the accuracy of inhalation therapy and (2) combination with biopharmaceuticals at an early stage. Errors in inhalation device usage and reduced patient adherence to inhalation techniques are common; therefore, establishing a medical coordination system to monitor patients' daily inhalation and provide support on how to solve these problems is essential. Furthermore, biopharmaceuticals such as anti-IL-5, anti-IL-4, anti-IgE, and anti-TSLP are currently available, with the use of new ones such as IL-33 expected in the future. The challenge is to combine these products with inhalation therapy and introduce them at an early stage. As such, the latest insights into these two issues will be discussed in this Special Issue.
Dr. Hiroyuki Ohbayashi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- asthma inhalation therapy
- biological therapy
- immunological mechanisms
- inhalation instruction
- inhalation guidance coordination system
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
